Intrinsic value of AxoGen - AXGN

Previous Close

$32.99

  Intrinsic Value

$0.18

stock screener

  Rating & Target

str. sell

-99%

Previous close

$32.99

 
Intrinsic value

$0.18

 
Up/down potential

-99%

 
Rating

str. sell

We calculate the intrinsic value of AXGN stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 1.1

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  35.70
  32.63
  29.87
  27.38
  25.14
  23.13
  21.32
  19.68
  18.22
  16.89
  15.70
  14.63
  13.67
  12.80
  12.02
  11.32
  10.69
  10.12
  9.61
  9.15
  8.73
  8.36
  8.02
  7.72
  7.45
  7.20
  6.98
  6.79
  6.61
  6.45
Revenue, $m
  82
  109
  141
  180
  225
  277
  336
  402
  476
  556
  644
  738
  839
  946
  1,060
  1,180
  1,306
  1,438
  1,576
  1,720
  1,870
  2,027
  2,189
  2,358
  2,534
  2,717
  2,906
  3,103
  3,309
  3,522
Variable operating expenses, $m
  83
  111
  144
  183
  229
  282
  342
  409
  483
  565
  653
  749
  852
  961
  1,076
  1,198
  1,326
  1,460
  1,600
  1,747
  1,899
  2,058
  2,223
  2,395
  2,573
  2,759
  2,951
  3,151
  3,360
  3,576
Fixed operating expenses, $m
  7
  7
  7
  8
  8
  8
  8
  8
  9
  9
  9
  9
  9
  9
  10
  10
  10
  10
  11
  11
  11
  11
  12
  12
  12
  12
  13
  13
  13
  13
Total operating expenses, $m
  90
  118
  151
  191
  237
  290
  350
  417
  492
  574
  662
  758
  861
  970
  1,086
  1,208
  1,336
  1,470
  1,611
  1,758
  1,910
  2,069
  2,235
  2,407
  2,585
  2,771
  2,964
  3,164
  3,373
  3,589
Operating income, $m
  -9
  -9
  -10
  -11
  -11
  -12
  -13
  -15
  -16
  -17
  -19
  -20
  -22
  -24
  -26
  -28
  -30
  -33
  -35
  -37
  -40
  -43
  -45
  -48
  -51
  -54
  -57
  -61
  -64
  -68
EBITDA, $m
  -8
  -8
  -9
  -9
  -10
  -10
  -11
  -11
  -12
  -13
  -14
  -15
  -16
  -17
  -18
  -19
  -20
  -22
  -23
  -24
  -26
  -27
  -29
  -30
  -32
  -34
  -35
  -37
  -39
  -41
Interest expense (income), $m
  0
  2
  3
  4
  6
  7
  9
  11
  14
  17
  20
  23
  27
  31
  35
  40
  45
  50
  55
  61
  67
  73
  80
  86
  93
  101
  108
  116
  124
  132
  141
Earnings before tax, $m
  -11
  -12
  -14
  -16
  -19
  -22
  -25
  -29
  -33
  -37
  -42
  -48
  -53
  -60
  -66
  -73
  -80
  -88
  -96
  -104
  -113
  -122
  -132
  -142
  -152
  -162
  -173
  -185
  -197
  -209
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -11
  -12
  -14
  -16
  -19
  -22
  -25
  -29
  -33
  -37
  -42
  -48
  -53
  -60
  -66
  -73
  -80
  -88
  -96
  -104
  -113
  -122
  -132
  -142
  -152
  -162
  -173
  -185
  -197
  -209

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  43
  57
  74
  94
  118
  145
  176
  210
  249
  291
  336
  385
  438
  494
  554
  616
  682
  751
  823
  899
  977
  1,059
  1,144
  1,232
  1,324
  1,419
  1,518
  1,621
  1,729
  1,840
Adjusted assets (=assets-cash), $m
  43
  57
  74
  94
  118
  145
  176
  210
  249
  291
  336
  385
  438
  494
  554
  616
  682
  751
  823
  899
  977
  1,059
  1,144
  1,232
  1,324
  1,419
  1,518
  1,621
  1,729
  1,840
Revenue / Adjusted assets
  1.907
  1.912
  1.905
  1.915
  1.907
  1.910
  1.909
  1.914
  1.912
  1.911
  1.917
  1.917
  1.916
  1.915
  1.913
  1.916
  1.915
  1.915
  1.915
  1.913
  1.914
  1.914
  1.913
  1.914
  1.914
  1.915
  1.914
  1.914
  1.914
  1.914
Average production assets, $m
  3
  4
  5
  7
  9
  11
  13
  15
  18
  21
  24
  28
  32
  36
  40
  45
  50
  55
  60
  65
  71
  77
  83
  90
  96
  103
  110
  118
  126
  134
Working capital, $m
  14
  19
  24
  31
  38
  47
  58
  69
  81
  95
  110
  126
  143
  162
  181
  202
  223
  246
  269
  294
  320
  347
  374
  403
  433
  465
  497
  531
  566
  602
Total debt, $m
  34
  47
  62
  80
  101
  126
  154
  185
  219
  257
  298
  342
  390
  440
  494
  550
  610
  672
  737
  804
  875
  949
  1,025
  1,105
  1,187
  1,273
  1,362
  1,455
  1,551
  1,652
Total liabilities, $m
  39
  51
  66
  85
  106
  130
  158
  189
  224
  262
  303
  347
  394
  445
  498
  555
  614
  676
  741
  809
  879
  953
  1,029
  1,109
  1,192
  1,277
  1,367
  1,459
  1,556
  1,656
Total equity, $m
  4
  6
  7
  9
  12
  14
  18
  21
  25
  29
  34
  39
  44
  49
  55
  62
  68
  75
  82
  90
  98
  106
  114
  123
  132
  142
  152
  162
  173
  184
Total liabilities and equity, $m
  43
  57
  73
  94
  118
  144
  176
  210
  249
  291
  337
  386
  438
  494
  553
  617
  682
  751
  823
  899
  977
  1,059
  1,143
  1,232
  1,324
  1,419
  1,519
  1,621
  1,729
  1,840
Debt-to-equity ratio
  7.970
  8.220
  8.400
  8.530
  8.620
  8.700
  8.750
  8.790
  8.820
  8.850
  8.870
  8.890
  8.900
  8.910
  8.920
  8.930
  8.940
  8.940
  8.950
  8.950
  8.950
  8.960
  8.960
  8.960
  8.970
  8.970
  8.970
  8.970
  8.970
  8.980
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -11
  -12
  -14
  -16
  -19
  -22
  -25
  -29
  -33
  -37
  -42
  -48
  -53
  -60
  -66
  -73
  -80
  -88
  -96
  -104
  -113
  -122
  -132
  -142
  -152
  -162
  -173
  -185
  -197
  -209
Depreciation, amort., depletion, $m
  1
  1
  1
  1
  2
  2
  3
  3
  4
  4
  5
  6
  6
  7
  8
  9
  10
  11
  12
  13
  14
  15
  17
  18
  19
  21
  22
  24
  25
  27
Funds from operations, $m
  -10
  -11
  -13
  -15
  -17
  -19
  -22
  -25
  -29
  -33
  -37
  -42
  -47
  -52
  -58
  -64
  -70
  -77
  -84
  -91
  -99
  -107
  -115
  -124
  -132
  -142
  -151
  -161
  -172
  -182
Change in working capital, $m
  4
  5
  6
  7
  8
  9
  10
  11
  13
  14
  15
  16
  17
  18
  19
  21
  22
  23
  24
  25
  26
  27
  28
  29
  30
  31
  32
  34
  35
  36
Cash from operations, $m
  -14
  -16
  -18
  -21
  -25
  -28
  -32
  -37
  -42
  -47
  -52
  -58
  -64
  -71
  -78
  -85
  -92
  -100
  -108
  -116
  -125
  -134
  -143
  -152
  -163
  -173
  -184
  -195
  -207
  -219
Maintenance CAPEX, $m
  0
  -1
  -1
  -1
  -1
  -2
  -2
  -3
  -3
  -4
  -4
  -5
  -6
  -6
  -7
  -8
  -9
  -10
  -11
  -12
  -13
  -14
  -15
  -17
  -18
  -19
  -21
  -22
  -24
  -25
New CAPEX, $m
  -1
  -1
  -1
  -1
  -2
  -2
  -2
  -3
  -3
  -3
  -3
  -4
  -4
  -4
  -4
  -5
  -5
  -5
  -5
  -5
  -6
  -6
  -6
  -6
  -7
  -7
  -7
  -7
  -8
  -8
Cash from investing activities, $m
  -1
  -2
  -2
  -2
  -3
  -4
  -4
  -6
  -6
  -7
  -7
  -9
  -10
  -10
  -11
  -13
  -14
  -15
  -16
  -17
  -19
  -20
  -21
  -23
  -25
  -26
  -28
  -29
  -32
  -33
Free cash flow, $m
  -15
  -17
  -20
  -24
  -28
  -32
  -37
  -42
  -47
  -53
  -60
  -67
  -74
  -81
  -89
  -97
  -106
  -115
  -124
  -133
  -143
  -154
  -164
  -176
  -187
  -199
  -212
  -224
  -238
  -252
Issuance/(repayment) of debt, $m
  10
  13
  15
  18
  21
  24
  28
  31
  34
  38
  41
  44
  47
  50
  53
  56
  59
  62
  65
  68
  71
  74
  76
  79
  83
  86
  89
  93
  96
  100
Issuance/(repurchase) of shares, $m
  13
  14
  16
  18
  21
  24
  28
  32
  37
  42
  47
  53
  59
  65
  72
  79
  87
  95
  103
  112
  121
  130
  140
  150
  161
  172
  183
  195
  207
  220
Cash from financing (excl. dividends), $m  
  23
  27
  31
  36
  42
  48
  56
  63
  71
  80
  88
  97
  106
  115
  125
  135
  146
  157
  168
  180
  192
  204
  216
  229
  244
  258
  272
  288
  303
  320
Total cash flow (excl. dividends), $m
  7
  9
  11
  13
  15
  17
  19
  21
  24
  26
  28
  30
  32
  34
  37
  39
  40
  42
  44
  46
  48
  50
  52
  54
  56
  59
  61
  63
  66
  68
Retained Cash Flow (-), $m
  -13
  -14
  -16
  -18
  -21
  -24
  -28
  -32
  -37
  -42
  -47
  -53
  -59
  -65
  -72
  -79
  -87
  -95
  -103
  -112
  -121
  -130
  -140
  -150
  -161
  -172
  -183
  -195
  -207
  -220
Prev. year cash balance distribution, $m
  23
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  17
  -5
  -5
  -6
  -6
  -7
  -9
  -11
  -13
  -16
  -19
  -22
  -26
  -31
  -36
  -41
  -46
  -53
  -59
  -66
  -73
  -80
  -88
  -96
  -104
  -113
  -122
  -132
  -142
  -152
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  17
  -4
  -5
  -5
  -5
  -5
  -6
  -7
  -7
  -8
  -9
  -10
  -10
  -10
  -10
  -10
  -10
  -10
  -9
  -8
  -8
  -7
  -6
  -5
  -4
  -3
  -3
  -2
  -2
  -1
Current shareholders' claim on cash, %
  65.5
  49.7
  38.9
  31.2
  25.5
  21.2
  17.7
  15.0
  12.8
  10.9
  9.4
  8.1
  7.1
  6.2
  5.4
  4.7
  4.1
  3.6
  3.2
  2.8
  2.5
  2.2
  1.9
  1.7
  1.5
  1.3
  1.2
  1.0
  0.9
  0.8

AxoGen, Inc. operates as a medical technology company. It offers a portfolio of nerve repair solutions for various surgical peripheral nerve repair needs. The company’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf human nerve allograft for bridging nerve discontinuities without the comorbidities associated with another surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. It also offers AcroVal neurosensory and motor testing system, which consists of AcroGrip for use in hand grip strength measurement; AcroPinch for measuring pinch strength; and Pressure-Specified Sensory Device, a somatosensory evaluation and measurement device, as well as provides AxoTouch two point discriminator, a tool used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals through a direct sales force and independent distributors. It markets its products in the United States, the United Kingdom, Israel, Canada, Greece, Chile, Switzerland, Austria, and Spain. AxoGen, Inc. is headquartered in Alachua, Florida.

FINANCIAL RATIOS  of  AxoGen (AXGN)

Valuation Ratios
P/E Ratio 0
Price to Sales 0
Price to Book 0
Price to Tangible Book
Price to Cash Flow 0
Price to Free Cash Flow 0
Growth Rates
Sales Growth Rate -100%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate NaN%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio NaN
Current Ratio NaN
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets 0%
Ret/ On Assets - 3 Yr. Avg. 0%
Return On Total Capital 0%
Ret/ On T. Cap. - 3 Yr. Avg. 0%
Return On Equity 0%
Return On Equity - 3 Yr. Avg. 0%
Asset Turnover 0
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin 0%
EBITDA Margin - 3 Yr. Avg. 0%
Operating Margin 0%
Oper. Margin - 3 Yr. Avg. 0%
Pre-Tax Margin 0%
Pre-Tax Margin - 3 Yr. Avg. 0%
Net Profit Margin 0%
Net Profit Margin - 3 Yr. Avg. 0%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

AXGN stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the AXGN stock intrinsic value calculation we used $60.426395 million for the last fiscal year's total revenue generated by AxoGen. The default revenue input number comes from 0001 income statement of AxoGen. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our AXGN stock valuation model: a) initial revenue growth rate of 35.7% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for AXGN is calculated based on our internal credit rating of AxoGen, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of AxoGen.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of AXGN stock the variable cost ratio is equal to 101.7%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $7 million in the base year in the intrinsic value calculation for AXGN stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 9.1% for AxoGen.

Corporate tax rate of 27% is the nominal tax rate for AxoGen. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the AXGN stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for AXGN are equal to 3.8%.

Life of production assets of 4.8 years is the average useful life of capital assets used in AxoGen operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for AXGN is equal to 17.1%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $25.182035 million for AxoGen - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 34.56 million for AxoGen is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of AxoGen at the current share price and the inputted number of shares is $1.1 billion.

RELATED COMPANIES Price Int.Val. Rating
IART Integra LifeSc 53.47 59.90  hold
PEN Penumbra 134.26 2.68  str.sell
NVTR Nuvectra 18.17 0.15  str.sell
NVRO Nevro 40.62 2.07  str.sell
LIVN LivaNova 122.91 2.55  str.sell

COMPANY NEWS

▶ AxoGen: 3Q Earnings Snapshot   [05:04PM  Associated Press]
▶ Medical technology company to create 200 new jobs in Dayton area   [02:48PM  American City Business Journals]
▶ Bull of the Day: Penumbra (PEN)   [Sep-25-18 05:05AM  Zacks]
▶ AxoGen, a medical tech company, inks deal for office space in Tampa Heights   [Sep-21-18 04:27PM  American City Business Journals]
▶ Here's Why AxoGen, Inc. Fell as Much as 18.6% Today   [Aug-02-18 03:44PM  Motley Fool]
▶ AxoGen: 2Q Earnings Snapshot   [Aug-01-18 05:30PM  Associated Press]
▶ Is It Too Late To Buy AxoGen Inc (NASDAQ:AXGN)?   [Jun-26-18 01:23PM  Simply Wall St.]
▶ AxoGen, Inc. to Present at Upcoming Investor Conferences   [Jun-06-18 07:00AM  GlobeNewswire]
▶ AxoGen Announces Proposed Public Offering of Common Stock   [May-07-18 04:04PM  GlobeNewswire]
▶ AxoGen: 1Q Earnings Snapshot   [Apr-30-18 05:31PM  Associated Press]
▶ AxoGen, Inc. to Host Earnings Call   [12:30PM  ACCESSWIRE]
▶ AxoGen, Inc. Announces 2018 Annual Shareholders Meeting   [Apr-12-18 07:00AM  GlobeNewswire]
▶ AxoGen (AXGN) Enters Overbought Territory   [Mar-27-18 12:22PM  Zacks]
▶ AxoGen reports 4Q loss   [Feb-28-18 05:03PM  Associated Press]
▶ AxoGen, Inc. to Host Earnings Call   [12:00PM  ACCESSWIRE]
▶ Best Growth Stock in February   [Feb-18-18 11:02AM  Simply Wall St.]
▶ Top 3 Growth Stocks For The Month   [Jan-17-18 11:02AM  Simply Wall St.]
▶ ETFs with exposure to AxoGen, Inc. : December 29, 2017   [Dec-29-17 11:32AM  Capital Cube]
▶ ETFs with exposure to AxoGen, Inc. : December 18, 2017   [Dec-18-17 02:41PM  Capital Cube]
▶ December Top Growth Stocks To Look Out For   [Dec-17-17 11:02AM  Simply Wall St.]
▶ ETFs with exposure to AxoGen, Inc. : December 1, 2017   [Dec-01-17 10:26AM  Capital Cube]
▶ AxoGen Announces Closing of Public Offering of Common Stock   [Nov-20-17 11:15AM  GlobeNewswire]
▶ ETFs with exposure to AxoGen, Inc. : November 16, 2017   [Nov-16-17 11:12AM  Capital Cube]
▶ November Growth Stocks To Look Out For   [11:02AM  Simply Wall St.]
▶ ETFs with exposure to AxoGen, Inc. : November 6, 2017   [Nov-06-17 11:08AM  Capital Cube]
▶ AxoGen reports 3Q loss   [Nov-01-17 06:45PM  Associated Press]
▶ Is AxoGen Inc (AXGN) A Financially Sound Company?   [Oct-31-17 12:35PM  Simply Wall St.]
▶ ETFs with exposure to AxoGen, Inc. : October 25, 2017   [Oct-25-17 09:51AM  Capital Cube]
▶ ETFs with exposure to AxoGen, Inc. : October 13, 2017   [Oct-13-17 10:31AM  Capital Cube]
▶ ETFs with exposure to AxoGen, Inc. : October 2, 2017   [Oct-02-17 10:41AM  Capital Cube]
▶ ETFs with exposure to AxoGen, Inc. : September 22, 2017   [Sep-22-17 10:16AM  Capital Cube]
▶ ETFs with exposure to AxoGen, Inc. : September 12, 2017   [Sep-11-17 09:19PM  Capital Cube]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.